Immunome, Inc.
IMNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $809,200 | $534,432 | $665,916 |
| - Cash | $272,639 | $143,876 | $257,613 | $143,351 |
| + Debt | $4,013 | $4,142 | $4,770 | $4,832 |
| Enterprise Value | – | $669,466 | $281,589 | $527,397 |
| Revenue | $0 | $4,015 | $2,926 | $2,738 |
| % Growth | -100% | 37.2% | 6.9% | – |
| Gross Profit | -$49,193 | $3,295 | $2,926 | $2,738 |
| % Margin | – | 82.1% | 100% | 100% |
| EBITDA | -$56,868 | -$45,758 | -$43,910 | -$55,003 |
| % Margin | – | -1,139.7% | -1,500.7% | -2,008.9% |
| Net Income | -$57,457 | -$43,397 | -$41,640 | -$80,249 |
| % Margin | – | -1,080.9% | -1,423.1% | -2,930.9% |
| EPS Diluted | -0.65 | -0.5 | -0.52 | -1.28 |
| % Growth | -30% | 3.8% | 59.4% | – |
| Operating Cash Flow | -$40,510 | -$49,401 | -$53,055 | -$42,060 |
| Capital Expenditures | -$1,116 | -$905 | -$3,665 | -$1,375 |
| Free Cash Flow | -$41,626 | -$50,306 | -$56,720 | -$43,435 |